[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-insufficiency-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-insufficiency-chronic":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,47,77,102,131,152,190,230,255,282,310,340,368,402,427,462,483,509,541,574,596,624,647,672,694],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622168","phase-4-anrikefon-vs-nalfurafine-for-sleep-quality-in-hemodialysis-patients-with-ckd-ap-100622168",false,"NCT07380113","Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP","An Exploratory Study Comparing Anrikefon With Nalfurafine in Improving Sleep Quality Among CKD-aP Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled Clinical Trial","Anrikefon","Inclusion Criteria:\n\n1. Be able to understand the procedures and methods of this trial, be willing to strictly follow the clinical research protocol to complete this trial, and voluntarily sign the informed consent form.\n2. Male or female individuals aged 18 or above and 75 or above.\n3. Patients with end-stage renal disease received regular hemodialysis three times a week before the screening period (whether they met the requirements for regular dialysis was determined based on the opinions of the researchers).\n4. Meet the diagnostic criteria for chronic kidney disease-associated pruritus (CKD-aP).\n\n   1. Patients with chronic kidney disease (CKD) presenting with pruritus, with other identifiable causes of pruritus excluded.\n   2. Pruritus occurring on at least 3 days within a 2-week period, with multiple episodes per day, each lasting for several minutes, and having an impact on the patient's daily life.\n   3. Recurrent pruritus persisting for at least 6 weeks.A diagnosis requires that all three criteria above be met simultaneously.\n5. The subjects were evaluated using the Worst Itch Numerical Rating Scale (WI-NRS) for the most severe pruritus intensity and met the baseline pruritus intensity of ≥ 4 points.\n6. The subjects have completed the Pittsburgh Sleep Quality Index (PSQI) assessment during the screening period and met the baseline PSQI score \\> 7 points.\n\nExclusion Criteria:\n\n1. Participants with other serious systemic diseases that may affect their ability to participate in the study, as assessed by the investigator, including but not limited to:\n\n   1. Severe cardiovascular diseases, such as unstable angina, myocardial infarction, severe arrhythmias, World Health Organization (WHO) heart function classification III-IV during screening, poorly controlled hypertension or hypotension despite active treatment, and recurrent asthma.\n   2. A history of cerebrovascular accident (CVA) within the last 6 months.\n   3. Malignant tumors, excluding those that are curable, such as cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin, or any other cancer that has been cured (with no evidence of disease recurrence for 5 years).\n2. It is expected to undergo kidney transplantation and\u002For parathyroidectomy during the study period.\n3. The subjects are currently undergoing ultraviolet B treatment or are expected to receive such treatment during the study period.\n4. Have participated in any clinical trials of other drugs or medical devices within one month prior to screening (treatment with drugs or medical devices that have received clinical trials).\n5. Patients who have used the following drugs within 7 days before screening:\n\n   1. those who have used opioids.\n   2. those who must use opioids other than the investigational drug during the study period.\n   3. those who has used gabapentin, pregabalin and calcineurin inhibitors;\n   4. those who use drugs that can affect the efficacy judgment of anti-itching, including but not limited to antipsychotic drugs, sedative-hypnotic drugs, selective serotonin reuptake inhibitors (SSRIs), anti-anxiety drugs, or tricyclic antidepressants.\n6. After screening and enrollment, new antihistamines (such as antihistamines and corticosteroids, etc. (oral, intravenous or topical)) were prescribed, or the types, dosages or frequencies of these drugs were changed.\n7. Patients who have used any hypnotic or sedative medications (including benzodiazepine hypnotics, non-benzodiazepine hypnotics, melatonin receptor agonists, etc.) within 1 month prior to the screening period and baseline assessment.\n8. There is a history of allergy to opioid drugs, or it is known that there is a history of allergy to investigatory drugs or components of remedial drugs or other drugs or excipients with similar chemical structures.\n9. Severe hematological and liver function abnormalities during screening, meeting any one of the following clinical laboratory test results:\n\n   1. Hematology: Hemoglobin \\\u003C 80g\u002FL.\n   2. Liver function:\n\n      * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.5× upper limit of normal (ULN).\n      * Total bilirubin (TBIL) \\> 2×ULN.\n10. Subjects who had any active infections during screening and whom the researchers considered unsuitable for inclusion (including but not limited to acute hepatitis, skin infections, etc.).\n11. As determined by the researchers, any other physical or mental illness or condition that may increase the risk of the trial, affect the subjects' compliance with the protocol, or affect the subjects' completion of the trial.","ALL","18 Years","75 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","The goal of this clinical trial is to compare a new intravenous drug, Anruikefen, with a traditional oral medication, nalfurafine orally disintegrating tablets, in improving sleep quality in patients with chronic kidney disease-associated pruritus. Sleep quality will be primarily assessed using the Pittsburgh Sleep Quality Index (PSQI). The study will also evaluate the safety of Anruikefen.\n\nThe main questions it aims to answer are:\n\n* Does Anruikefen injection improve sleep quality better than oral nalfurafine?\n* Does Anruikefen injection improve patients' quality of life more than oral nalfurafine? Researchers will compare Anruikefen with nalfurafine (an active control drug) to evaluate differences in their effects on sleep quality in patients with chronic kidney disease-associated pruritus.\n\nParticipants will:\n\n* Receive either Anruikefen injection (0.3 μg\u002Fkg, three times per week) or nalfurafine hydrochloride orally disintegrating tablets (2.5 μg once daily).\n* Continue treatment for 4 weeks, followed by a 1-week safety follow-up.\n* Complete the Pittsburgh Sleep Quality Index and other quality-of-life questionnaires after one month.",[29,30,31,32,33,34],"Pruritus Chronic","Kidney Diseases, Chronic","Renal Insufficiency, Chronic","Uremia; Chronic","Pruritus Due to Systemic Disorder (Disorder)","Pruritus Due to Hemodialysis","NOT_YET_RECRUITING","2026-06-14",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":23},"2026-07-01",{"date":43,"type":23},"2027-12-31",{"name":45,"class":46},"Zhujiang Hospital","OTHER",{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100519711","multi-parametric-mri-evaluation-of-renal-graft-performance-after-living-donor-donation-100519711","NCT06047106","Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation.","DOVIMIR : Multi-parametric MRI Evaluation of Renal Graft Performance After Living Donor Donation","DOVIMIR","Inclusion Criteria:\n\nFor recipients:\n\n* Patients with end-stage chronic kidney disease awaiting kidney transplant from a living donor.\n* Adult patient\n* Consent signed\n* effective contraceptive method for women\n* Patient affiliated to a social security or beneficiaries of a similar scheme\n\nFor donors:\n\n* Individuals eligible for living kidney donation with GFR \\> 60 mL\u002Fmin\u002F1.73 m².\n* Adult patient\n* Consent signed\n* effective contraceptive method for women\n* Patient affiliated to a social security or beneficiaries of a similar scheme\n\nExclusion Criteria:\n\nFor the two groups :\n\n* MRI contraindications (claustrophobia, pacemaker, cardioverter defibrillators implantable, mechanical heart valve non MRI-compatible)\n* Weight\\> 130 kg\n* Pregnant, parturient or breastfeeding\n* Persons deprived of their liberty by a judicial or administrative decision,\n* Adults subject to a legal protection measure (safeguard measure, guardianship, curators)\n* subject participating in another research including an exclusion period still in progress at inclusion\n\nFor recipients :\n\n\\- Contraindication to renal graft biopsy (ongoing or uninterrupted anticoagulant or antiplatelet treatment, thrombocytopenia \\\u003C100 x 10\\^9\u002FL, anemia \\\u003C7 g\u002FdL).",{"count":56,"type":23},80,[58],"NA","The selection of kidneys from living donors is based on strict glomerular filtration rate (GFR) values, in the setting of the increasing proportion of older donors. The 2017 KDIGO recommendations consider that approving kidney donation for a donor with a GFR between 60 and 89 mL\u002Fmin\u002F1.73 m² should be individually discussed, possibly using a calculator. A GFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² should contraindicate donation without considering the donor's age.\n\nGFR physiologically decreases with age, so older donors frequently have a GFR below 90 ml\u002Fmin\u002F1.73 m². However, the proportion of older donors continues to rise.\n\nKidney grafts from older living donors maintain better renal function than those from deceased donors, aiming to counteract the organ shortage.\n\nKidneys possess functional reserves, allowing an increase in GFR during stimulations and adaptation to reduced functional nephron count (as after nephrectomy). Assessing this adaptive capacity clinically is challenging. It might be dependent on vascularization and\u002For absence of fibrosis, but these parameters are poorly understood due to a lack of current in vivo exploration methods.\n\nThe development of functional renal MRI enables the evaluation of these parameters, allowing measurements on separate, regional, non-invasive, quantitative kidney segments coupled with morphological studies. BOLD-MRI can measure regional oxygen content, thus accessing more precise medullary data. The DWI sequence can estimate renal microstructure and study interstitial fibrosis.\n\nTherefore, evaluating renal performance (by measuring GFR, renal perfusion, fibrosis, inflammation, and oxygen content) in donors, and studying the evolution of these parameters in recipients and donors, could optimize donor selection.\n\nHence, the aim of our study is to 1) investigate the evolution of renal functional parameters in the transplanted kidney up to 1 year post-transplant, and 2) study the evolution of these same parameters in the contralateral kidney of the donor.",[31],[62,63,64,65],"Living Donor Donation","multiparametric MRI","ischemia reperfusion injury","kidney graft","RECRUITING","2026-06-05",{"date":69,"type":39},"2026-06-09",{"date":71,"type":39},"2024-05-07",{"date":73,"type":23},"2029-09",{"name":75,"class":46},"Hospices Civils de Lyon",1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100637279","phase-3-a-phase-iii-study-to-evaluate-the-effect-of-balcinrenonedapagliflozin-in-patients-with-ckd-stage-3b-and-4-balanced-ckd-100637279","NCT07624305","A Phase III Study to Evaluate the Effect of Balcinrenone\u002FDapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)","A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone\u002FDapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of CKD and at least one of the following:\n\n  1. eGFR ≥ 15 to \\\u003C 45 mL\u002Fmin\u002F1.73 m2 AND: UACR ≥ 30 mg\u002Fg (central laboratory) or UACR ≥ 100 mg\u002Fg (local laboratory ) or UPCR ≥ 200 mg\u002Fg (local laboratory).\n  2. eGFR ≥ 15 to \\\u003C 30 mL\u002Fmin\u002F1.73 m2 and UACR \\\u003C 30 mg\u002Fg (local or central laboratory UACR value).\n* Serum\u002Fplasma K+ ≤ 5.0 mmol\u002FL\n* Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening.\n\nExclusion Criteria:\n\n* Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation\n* UACR ≥ 5000 mg\u002Fg or UPCR ≥ 7000 mg\u002Fg at screening.\n* SBP \\> 180 mmHg or DBP \\> 110 mmHg at screening.\n* SBP \\\u003C 90 mmHg at screening.\n* HbA1c \\> 9% at screening\n* T1DM, except:\n\n  1. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible.\n  2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion.\n* Autosomal dominant polycystic kidney disease.\n* Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening.\n* Severe hepatic impairment (Child-Pugh Class C).\n* Adrenal insufficiency.\n* Clinically significant acute kidney injury within 12 weeks prior to the screening.\n* New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening.\n* Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening.\n* Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation.\n* Any use of the following medications and supplements:\n\n  1. MRAs\n  2. Aldosterone analogues\n  3. Aldosterone synthase inhibitors\n  4. Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation.\n  5. Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation","99 Years",{"count":86,"type":23},2800,[88],"PHASE3","The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \\\u003C 45 mL\u002Fmin\u002F1.73 m2) administered orally once daily in addition to SoC.\n\nThis is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.",[31],"2026-05-29",{"date":93,"type":39},"2026-06-03",{"date":95,"type":23},"2026-09-01",{"date":97,"type":23},"2030-07-01",{"name":99,"class":100},"AstraZeneca","INDUSTRY",45,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":110,"targetDuration":4,"studyType":24,"phases":112,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100281766","phase-2-neurovascular-transduction-during-exercise-in-chronic-kidney-disease-100281766","NCT02947750","Neurovascular Transduction During Exercise in Chronic Kidney Disease","Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease","NeurovEx","Inclusion Criteria for Chronic Kidney Disease Patients:\n\n* Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc\u002Fminute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n* Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months\n* Does not exercise regularly (defined as exercising less than 20 minutes twice per week)\n* Willing and able to cooperate with the study protocol\n\nInclusion Criteria for Control Study Participants:\n\n* Does not exercise regularly (defined as exercising less than 20 minutes twice per week)\n* Willing and able to cooperate with the study protocol\n\nExclusion Criteria:\n\n* severe CKD (eGFR\\\u003C15 cc\u002Fminute)\n* ongoing drug or alcohol abuse\n* diabetic neuropathy\n* any serious systemic disease that might influence survival\n* severe anemia with hgb level \\\u003C9 g\u002FdL\n* clinical evidence of congestive heart failure or ejection fraction below 35%\n* symptomatic heart disease determined by prior electrocardiogram, stress test, and\u002For history\n* treatment with central alpha agonists (clonidine)\n* uncontrolled hypertension with BP greater than 170\u002F100 mm Hg\n* low blood pressure with BP less than 100\u002F50\n* pregnancy or plans to become pregnant\n* current treatment with monoamine oxidase (MAO) inhibitors\n* inability to exercise on a stationary bicycle",{"count":111,"type":23},150,[113],"PHASE2","The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and\u002For treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.",[31],[117,118,119,120],"Hypertension","Kidney Disorder","Nephrology","Physiology","2026-05-14",{"date":123,"type":39},"2026-05-18",{"date":125,"type":39},"2016-10",{"date":127,"type":23},"2027-04-30",{"name":129,"class":46},"Emory University",3,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":76},"100563645","time-restricted-eating-in-patients-with-moderate-chronic-kidney-disease-and-albuminuria-100563645","NCT06618859","Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria","Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria: A Pilot Randomized, Open-label, Double-arm Trial (TRECK)","TRECK","Inclusion Criteria:\n\n* Clinical criteria\n\n  * Adult men and women\n  * Chronic Kidney Disease with KDIGO stage G2 and G3 defined by a Glomerular Filtration Rate between 30 and 90 mL\u002Fmin\u002F1.73m2\n  * Albuminuria stage A2 or A3, but without nephrotic-range proteinuria: 3 to 200 mg\u002Fmmol\n  * Body mass index 18-40 kg\u002Fm2\n  * Eating window of 12 hours (self-reported and measured during the run-in phase)\n* Study-related criteria\n\n  * Able to give informed consent and follow the study procedures for the entire duration\n  * Confident use of a smartphone compatible with the MyFoodRepo app (iOS, Android) and able to take regular pictures of food\u002Fdrinks\n\nExclusion Criteria:\n\n* Clinical criteria\n\n  * Pregnant and breastfeeding women, plans for maternity during the study\n  * Eating disorder(s)\n  * Other diets: low-carb, ketogenic diet, hypocaloric diets (eviction for food intolerances, vegan\u002Fvegetarian diet are not excluded)\n  * Uncontrolled blood pressure (\\> 160\u002F100 mmHg)\n  * Diabetes with hypoglycemic drug(s) will be excluded, however those with impaired glucose tolerance (prediabetes, as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included\n  * Oral corticosteroids\n  * Uncontrolled diabetes HbA1c \\> 8.5%\n  * Active cancer and\u002For oncologic treatment over the previous 12 months\n  * Major mental illness\n  * Consumption of \\> 7 standard units of alcohol per week for women and \\> 14 standard units of alcohol per week for men\n  * Shift work, such as evening shifts or night shifts planned during the study\n  * Travel\u002Ftrip to a different time zone (≥ 2-hour time difference) planned during the study\n* Study-related criteria and other interventions\n\n  * Recent treatment modification in the last 3 months, including but not limited to ACE blockers, SLGT2i, finerenone\n  * Patients with recent glomerulonephritis diagnosis on more than 2 immunosuppressive drugs\n  * Patients with kidney transplant in the last past year\n  * Enrolled in another interventional clinical trial (medication, medical device) over the previous 1 month and planned during the study",{"count":22,"type":23},[58],"Chronic kidney disease (CKD) affects approximately 12 to 15% of adults worldwide, with an increasing incidence expected. Major causes include diabetic nephropathy, hypertension, and various glomerulonephritis. Proteinuria is a key factor in identifying and assessing the risk of CKD progression.\n\nThe precise pathophysiology of CKD is not fully understood, but recent research highlights metabolic alterations, particularly in lipid and glucose metabolism. CKD progression is influenced by diet, as evidenced by recent studies. Interventions such as the ketogenic diet and time-restricted feeding show promising results in improving metabolism and may have beneficial effects on CKD.\n\nOur study aims to evaluate the impact of time-restricted eating (TRE) on proteinuria, the decline in glomerular filtration rate, and weight loss in patients with moderate CKD with albuminuria (KDIGO stage 2-3). This will allow us to better understand the efficacy of this dietary approach tailored to the individual habits of participants.\n\nThe primary outcome measure will be albuminuria before and after the 12-week intervention. Secondary outcome measures will include the impact of fasting on blood pressure as assessed by 24-hour ambulatory monitoring, body composition evaluated by DXA and BIA, continuous glucose monitoring, and blood hormone profiles. Additionally, the feasibility and safety of TRE in this population will be assessed.",[31],"2026-05-08",{"date":145,"type":39},"2026-05-11",{"date":147,"type":39},"2024-12-04",{"date":149,"type":23},"2027-12",{"name":151,"class":46},"de Seigneux Sophie",{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":161,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100633150","ai-guided-relaxation-for-hemodialysis-anxiety-100633150","NCT07522944","AI-Guided Relaxation for Hemodialysis Anxiety","Artificial Intelligence-Guided Relaxation Interventions for Reducing Anxiety and Enhancing Coping Strategies in Patients Undergoing Hemodialysis","Inclusion Criteria:\n\nAdult patients aged 18 years or older Confirmed diagnosis of end-stage renal disease (ESRD) receiving maintenance hemodialysis for at least 3 months to ensure treatment stability Conscious, oriented, and able to communicate effectively Documented baseline anxiety at a mild-to-moderate level confirmed on initial screening using the GAD-7 or HADS prior to enrollment Adequate visual and auditory functions sufficient to interact with the AI-guided relaxation platform Willing to participate and provide written informed consent prior to enrollment\n\nExclusion Criteria:\n\nHistory of epilepsy, chronic vertigo, or seizure disorders, as AI or VR visual stimuli may trigger adverse episodes Severe cognitive impairment or diagnosed psychiatric disorders such as dementia or schizophrenia that prevent comprehension of or adherence to study instructions Acute medical complications or hemodynamic instability occurring during the dialysis session Severe visual impairment or blindness precluding use of the digital relaxation interface Skin infections or injuries on the face or head preventing comfortable use of a headset where applicable Currently enrolled in any other psychological or relaxation intervention study",{"count":160,"type":23},60,[58],"This study aims to evaluate whether a relaxation program guided by Artificial Intelligence (AI) can help reduce anxiety and improve coping mechanisms for patients receiving maintenance hemodialysis. Patients undergoing dialysis often face significant psychological stress and physical discomfort. This research uses a randomized controlled trial (RCT) with a parallel-group, pretest-posttest controlled design to compare patient well-being before and after using the AI-guided intervention.\n\nParticipants will engage with an AI system designed to provide personalized relaxation techniques during their dialysis sessions. The study uses a mixed-methods approach. Quantitative: Researchers will use standardized scales to measure changes in anxiety levels, depression, coping strategies, and perceived relaxation. Qualitative: Researchers will conduct interviews with participants to understand their personal experiences, how they engaged with the AI technology, and how it influenced their ability to manage the stress of their treatment.",[31,164,165,166,167],"Anxiety","Relaxation Therapy","Maintenance Hemodialysis","Stress, Psychological",[169,170,171,172,164,173,174,165,175,176,177,178,179],"Hemodialysis, Hospital","Renal Dialysis","End-Stage Renal Disease (ESRD)","Psychological Distress","Artificial Intelligence","Digital Health","Mindfulness-Based Interventions","Coping Skills","AI-Guided Intervention","Virtual Reality (VR)","Immersive Technology","2026-05-07",{"date":182,"type":39},"2026-05-12",{"date":184,"type":39},"2026-03-29",{"date":186,"type":23},"2026-05-30",{"name":188,"class":46},"Alexandria University",2,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":24,"phases":200,"briefSummary":201,"conditions":202,"keywords":213,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":76},"100627258","kidney-transplant-improvement-through-new-exercise-training-to-increase-capacity-100627258","NCT07446296","Kidney Transplant Improvement Through New Exercise Training to Increase Capacity","KINETIC -- Kidney Transplant Improvement Through New Exercise Training to Increase Capacity","KINETIC","Inclusion Criteria:\n\n* be at least 60 years old\n* receive transplant care at Penn Medicine\n* be on the kidney transplant waiting list\n* speak and comprehend English\n* be able to walk\n* have at least one physical function limitation OR at least one frailty metric\n* have access to a device capable of connecting to the Internet and downloading an application\n* be able to provide written informed consent\n* be cleared for participant via the Physical Activity Readiness Questionnaire (PARQ) verified against medical record or via written medical clearance from a clinician\n\nExclusion Criteria:\n\n* Have had a myocardial infarction or a stroke in the 3 months immediately prior to enrollment\n* Be unable to self-monitor with study devices (i.e., have a condition such as dementia)\n* Not cleared by PARQ or receive written medical clearance to exercise\n* Participate in another physical activity study\n* Have any other reason they do not expect to be able to complete the study","60 Years",{"count":160,"type":23},[58],"The goal of this clinical trial is to learn if a home-based exercise program can be safely and feasibly used to improve physical activity and physical function in adults waiting for a kidney transplant. The study will also learn how acceptable and useful this program is for participants.\n\nThe main questions it aims to answer are:\n\n* Can a remote exercise program be delivered successfully to people on the kidney transplant waiting list?\n* Do participants follow the exercise program and wear a physical activity tracker as asked?\n* Is the program safe and well tolerated?\n\nResearchers will compare two groups to see if the exercise program leads to higher physical activity and better physical function:\n\n* Usual pre-transplant care with a physical activity tracker\n* Usual pre-transplant care plus an online exercise program\n\nParticipants will:\n\n* Wear a wrist activity tracker to measure daily physical activity\n* Complete a one-week baseline period before being assigned to a study group\n* Be randomly assigned (like flipping a coin) to one of two groups\n* If assigned to the exercise group, take part in online exercise classes at home for 12 weeks with reminders and feedback, and then another 12 weeks without reminders and feedback\n* Answer questionnaires about their health, activity, and experience in the study\n\nThis study may help researchers learn how to better support people waiting for kidney transplant through safe, home-based exercise programs.",[203,204,205,206,207,208,209,210,211,212],"Chronic Kidney Disease 5D","Chronic Kidney Disease Stage 5","Kidney Failure","Kidney Failure,Chronic","Renal Insufficiency Chronic","Chronic Kidney Disease Stage 4","Kidney Transplantation","Waiting List","Transplant Candidate","Exercise Theraphy",[214,215,216,217,218,219,220],"kidney transplant candidates","prehabilitation","home-based exercise","physical activity program","kidney transplant waiting list","pre-transplant care","physical function","2026-05-05",{"date":223,"type":39},"2026-05-06",{"date":225,"type":39},"2026-03-24",{"date":227,"type":23},"2028-05",{"name":229,"class":46},"University of Pennsylvania",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":237,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":253,"locationsCount":76},"100613111","phase-1-a-trial-of-hydroxynidone-capsules-in-single-dose-administration-for-patients-with-renal-insufficiency-100613111","NCT07262333","A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency","Safety and Pharmacokinetics of Single-dose Hydroxynidone Capsules in Patients With Renal Insufficiency","Inclusion Criteria:\n\n* The subjects must meet all of the following criteria to be eligible for inclusion:\n* (1) Healthy Chinese subjects, with an estimated glomerular filtration rate (absolute eGFR) meeting the following conditions: ≥ 90 mL\u002Fmin and \\\u003C 130 mL\u002Fmin; (limited to healthy subjects)\n* (2) Patients diagnosed with renal dysfunction, with the estimated glomerular filtration rate (absolute eGFR) for mild, moderate, and severe renal dysfunction meeting the following standards respectively: 1. Mild renal dysfunction 60-89 mL\u002Fmin; 2. Moderate renal dysfunction 30-59 mL\u002Fmin; 3. Severe renal dysfunction 15-29 mL\u002Fmin; (limited to patients with renal dysfunction)\n* (3) Age 18-70 years old, inclusive of 18 years and 70 years old;\n* (4) Weight: Male ≥ 50 kg, female ≥ 45 kg, 18 ≤ BMI ≤ 28 (BMI = weight (kg) \u002F height2 (m2));\n* (5) During the 24 hours before the start of the trial to the end of the trial, the subjects agree to quit smoking, alcohol, fruit juices, caffeine, and tea;\n* (6) Before the trial, they have fully understood the nature, significance, possible benefits, possible inconveniences, and potential risks of the trial, and voluntarily participated in this clinical trial, can communicate well with the researchers, comply with all the requirements of the entire study, and have the ability to understand and sign the written informed consent form.\n\nExclusion Criteria:\n\n* The following conditions must be met for a subject to be eligible for this trial:\n* (1) If the subject has participated in any other clinical trial within the three months prior to the trial;\n* (2) If the subject has any disease that may affect the safety of the trial or the body's process of the drug, excluding renal insufficiency, including but not limited to: previous or existing diseases of the heart, liver, digestive tract, immune system and respiratory system (especially any gastrointestinal diseases that affect drug absorption, such as irritable bowel syndrome symptoms, intestinal diseases or inflammatory bowel disease history, active pathological bleeding (such as peptic ulcers), urticaria, epilepsy, allergic rhinitis, eczematous dermatitis, asthma, etc.); (limited to patients with renal insufficiency);\n* (3) If the subject has any disease that may affect the safety of the trial or the body's process of the drug, including but not limited to: previous or existing diseases of the heart, liver, kidney, endocrine, digestive tract, immune system and respiratory system (especially cardiovascular diseases including those with cardiovascular disease risk, any gastrointestinal diseases that affect drug absorption (such as irritable bowel syndrome symptoms, intestinal diseases or inflammatory bowel disease history), active pathological bleeding (such as peptic ulcers), urticaria, epilepsy, allergic rhinitis, eczematous dermatitis, asthma, etc.); (limited to healthy subjects);\n* (4) If the subject has an allergic constitution: if there is a history of allergy to two or more drugs (including the trial drug), food, or lactose intolerance;\n* (5) If the subject has used any drugs that inhibit or induce the liver's metabolism of the drug within 28 days before taking the study drug (common liver enzyme inducers: barbiturates, carbamazepine, amiloride, griseofulvin, amitriptyline, phenytoin, grumet, rifampicin, dexamethasone; common liver enzyme inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol, isoniazid, sulfonamide drugs);\n* (6) If the subject has used drugs that inhibit or induce SULT and UGT enzymes within 7 days before taking the study drug and cannot stop the use;\n* (7) If the subject cannot tolerate venipuncture and\u002For has a history of fainting or needle shock;\n* (8) If the subject has long-term excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup = 250 mL) in the past; or if within 24 hours before the first administration of the study drug, the subject consumed any food or beverage that inhibits or induces liver metabolic enzymes (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., which contain rich flavonoids or citrus glycosides compounds); or if within 24 hours before the first administration of the study drug, the subject took any product containing alcohol;\n* (9) If the subject has consumed blood or had a large amount of bleeding (more than 450 mL) within 3 months before the first administration of the study drug, or plans to donate blood or blood components during or after the study;\n* (10) If the subject has donated blood or had a large amount of bleeding (more than 450 mL) within 3 months before the first administration of the study drug, or plans to donate blood or blood components during or after the study;\n* (11) If the subject has acute diseases during the screening stage of the study or before taking the study drug;\n* (12) If the subject has consumed foods or beverages that inhibit or induce liver metabolic enzymes within 24 hours before the first administration of the study drug (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., which contain rich flavonoids or citrus glycosides compounds);\n* (13) If the subject is pregnant or breastfeeding, and the subject (or their partner) has a pregnancy plan during and after the study, and does not agree to use non-drug measures for contraception during the study period;\n* (14) (Medical Inquiry) Those who underwent surgery within three months prior to the screening period, or those planning to undergo surgery during the study period, and those who have undergone surgeries that may affect drug absorption, distribution, metabolism, and excretion;\n* (15) Those with a history of drug use or drug abuse;\n* (16) Those who smoked more than 5 cigarettes per day within 14 days prior to the screening, or those who cannot stop using any tobacco products during the trial;\n* (17) Those who smoked or used any tobacco products during the screening to admission period;\n* (18) During the screening period, abnormalities in physical examination, electrocardiogram, and laboratory tests (including routine blood and urine tests, coagulation function, and pregnancy test for women of childbearing potential only) that are judged by the investigator as clinically significant (excluding those caused by renal insufficiency). For liver function tests: ALT \\> 3×ULN or AST \\> 3×ULN or T-BIL \\> 2×ULN or D-BIL \\> 2×ULN; for lipid tests: TG ≥ 5.6 mmol\u002FL; for serum electrolyte tests (K+, Na+, Cl-, Ca2+): abnormalities indicating hyperkalemia or a tendency toward acidosis (limited to patients with renal insufficiency).\n* (19) Those whose physical examination, vital sign measurement, electrocardiogram examination, laboratory tests \\[blood routine, urine routine, blood biochemistry, coagulation function, blood pregnancy (only for women of childbearing age)\\] as determined by the researchers show abnormal results with clinical significance; (for healthy subjects)\n* (20) Those with positive nicotine test results;\n* (21) Those with alcohol breath test results greater than 0.0 mg\u002F100 ml;\n* (22) Those with positive urine drug screening results;\n* (23) Those with positive hepatitis B surface antigen, or hepatitis C antibody, or syphilis spirochete antibody, or HIV antibody test results positive;\n* (24) Those who, as determined by the researchers, have any situation that may affect the subject's provision of informed consent or compliance with the trial protocol, or who participating in the trial may affect the trial results or their own safety.",true,"70 Years",{"count":240,"type":23},56,[242],"PHASE1","Hydronidone capsules are pyridinone-based small molecule compounds. Hydronidone has not been approved for commercial sale both domestically and internationally. The applicant has completed the preliminary Phase I and Phase II clinical trials. The results showed that Hydronidone is a safe and effective drug for treating liver fibrosis in chronic hepatitis B, and it has good safety and tolerability.\n\nBased on the preliminary clinical research, a special population study has been initiated. The aim is to investigate the pharmacokinetic differences and safety of honginone capsules in patients with renal insufficiency and healthy subjects, in order to provide a basis for the clinical medication of patients with renal dysfunction.",[207],[246],"Hydroxynidone","2026-04-02",{"date":249,"type":39},"2026-04-06",{"date":251,"type":39},"2025-12-25",{"date":41,"type":23},{"name":254,"class":100},"Beijing Continent Pharmaceutical Co, Ltd.",{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":237,"sex":18,"minAge":19,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":24,"phases":265,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":189},"100625726","phase-1-a-study-of-eloralintide-ly3841136-in-participants-with-renal-impairment-and-in-participants-with-normal-renal-function-100625726","NCT07426380","A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function","A Phase 1, Multicenter, Parallel-Design, Single Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Eloralintide in Participants With Severe Renal Impairment and End Stage Renal Disease (ESRD) Compared With Participants With Normal Renal Function","Inclusion Criteria:\n\n* Have a body weight of 55 kilograms (kg) or more and a body mass index (BMI) within the range of 19.0 to 40.0 kilograms per square meter (kg\u002Fm²), inclusive\n* Have no significant history of spontaneous or ethanol-induced hypoglycemia\n\nAdditional Inclusion Criteria for Group 1\n\n* Are healthy as determined by medical history, physical examination, and other screening procedures, with normal renal function, assessed by estimated glomerular filtration rate (eGFR) of at least 90 milliliters per minute (mL\u002Fmin)\n* Have glycated hemoglobin (HbA1c) less than or equal to 6.5% at screening\n\nAdditional Inclusion Criteria for Groups 2 and 3\n\n* Have stable severe renal impairment, assessed by eGFR less than 30 mL\u002Fmin at screening or with end-stage renal disease (ESRD) who have been on a stable hemodialysis (HD) schedule for at least 3 months prior to planned dosing\n* Have acceptable blood pressure and pulse rate\n* If participants have Type 2 Diabetes Mellitus (T2DM), they must have a HbA1c equal to or less than 10.0% at screening\n\nExclusion Criteria:\n\n* Have a history of chronic liver disease, acute or chronic hepatitis, including a history of autoimmune hepatitis, any evidence for hepatic impairments\n* Have a current, functioning organ transplant. Nonfunctional renal allografts may be considered\n* Have significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, dermatological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the investigational product; or interfering with the interpretation of data\n\nGroups 2 and 3\n\n* Are receiving continuous HD or peritoneal dialysis.\n* Have used any drug indicated for medical care of the participant's renal impairment, which is not established in dose and administered for at least 7 days before eloralintide administration","85 Years",{"count":264,"type":23},28,[242],"The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin).\n\nFor each participant, the study will last about 14 weeks, excluding screening.",[268,207,269,270,271,272],"Kidney Disease","Kidney Failure, Chronic","Renal Impairment","Renal Insufficiency","End Stage Kidney Disease","2026-03-12",{"date":275,"type":39},"2026-03-13",{"date":277,"type":39},"2026-02-24",{"date":279,"type":23},"2026-10",{"name":281,"class":100},"Eli Lilly and Company",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":289,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":24,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":76},"100627341","exercise-during-hemodialysis-impact-on-sarcopenia-and-sleep-quality-100627341","NCT07447375","Exercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality","Intrahospital Exercise Program in Hemodialysis Patients: Impact on Sarcopenia Markers, Sleep Quality, and Quality of Life.","Inclusion Criteria:\n\n* Subjects currently enrolled in a Chronic Hemodialysis Unit.\n* Patients who have been on hemodialysis treatment for more than 3 months.\n* Subjects aged 40 years or older.\n* Hemoglobin levels greater than 10 mg\u002Fdl.\n* Ability to perform physical fitness assessment tests or dynamometry.\n* Willingness and ability to provide signed informed consent\n\nExclusion Criteria:\n\n* Presence of intradialytic instability.\n* Medical conditions where exercise is contraindicated: active infectious process, neoplasms, uncontrolled arrhythmias, or left ventricular dysfunction (EF \\\u003C 35%).\n* Musculoskeletal or respiratory alterations that worsen with exercise.\n* Lower limb amputation without a prosthesis.\n* Cerebrovascular disease (stroke with sequelae or transient ischemic attacks within the previous 6 weeks).\n* Uncontrolled hypertension (Systolic BP \\> 200 mmHg or Diastolic BP \\> 120 mmHg).\n* Unstable angina (at rest or during exercise) or history of coronary bypass\u002Fischemic heart disease within the previous 6 weeks.\n* Diabetes mellitus with severe decompensation (blood glucose \\> 300 mg\u002Fdl).\n* Dialysis-related hypotension (mean blood pressure \\\u003C 90\u002F70 mmHg).\n* Psychiatric or cognitive alterations that prevent collaboration with muscle training programs.\n* Presence of an arteriovenous fistula in a lower limb.\n* Motor neurological injury causing dysfunction that prevents the application of the strength protocol.\n* Hospitalization within the 3 months prior to the study.\n* Lack of cooperation (defined as failing to attend more than 25% of sessions) or inability to understand the treatment.","40 Years",{"count":291,"type":23},58,[58],"Sarcopenia (the loss of muscle mass, strength, and function) is highly prevalent in patients with Chronic Kidney Disease (CKD) undergoing hemodialysis, significantly increasing the risk of falls, frailty, and mortality. Despite its impact, there is a lack of evidence regarding the effectiveness of exercise programs specifically designed to address sarcopenia under the latest international diagnostic criteria (EWGSOP2) in older renal patients.\n\nThe primary objective of this randomized controlled clinical trial is to evaluate the effects of a 12-week supervised intrahospital exercise program on muscle mass, strength, and physical performance in hemodialysis patients over 40 years of age. Additionally, the study aims to analyze how this intervention influences sleep quality-often disrupted in this population-and overall health-related quality of life.\n\nParticipants will be randomly assigned to either an Intervention Group, which will perform personalized strength and aerobic exercises during the first 90 minutes of their dialysis sessions, or a Control Group, receiving standard care. Evaluations will be conducted at three points: baseline (pre-randomization), at 12 weeks (post-intervention).\n\nThe investigators hypothesize that integrating physical exercise into the routine clinical care of hemodialysis patients will improve sarcopenia markers and sleep patterns, leading to greater functional independence and better clinical outcomes.",[295,31],"Sarcopenia",[297,298,299,300],"Hemodialysis","Intradialytic Exercise","Sleep Quality","Quality of Life","2026-02-27",{"date":303,"type":39},"2026-03-03",{"date":305,"type":39},"2026-01-02",{"date":307,"type":23},"2027-06-30",{"name":309,"class":46},"University of Salamanca",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":237,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":320,"phases":4,"briefSummary":321,"conditions":322,"keywords":326,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":76},"100627097","transformative-research-in-diabetic-nephropathy-20-100627097","NCT07444203","Transformative Research in Diabetic Nephropathy 2.0","Transformative Research in Diabetic Nephropathy 2.0: A Proof of Principle Study of SGLT2 Inhibitors (TRIDENT 2.0)","TRIDENT 2","Inclusion Criteria:\n\n* Age ≥18 years\n* eGFR ≥10 ml\u002Fmin\u002F1.73 m2 based on the 2021 race-free CKD-EPI equation13\n* Underwent a clinically indicated kidney biopsy, living donor biopsy, or nephrectomy (non-tumor adjacent tissue available).\n* Able and willing to provide informed consent for release of one pathology and clinical data abstraction.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Archived biopsy or surgical tissue unavailable for slide preparation.\n* Any local institutional policy that prohibits release of H\\&E slides for research.",{"count":319,"type":23},200,"OBSERVATIONAL","The goal of this observational study is to learn more about kidney health in adults with diabetic kidney disease and other groups. Researchers will study kidney tissue and other samples. They want to learn how sodium-glucose cotransporter-2 (SGLT2) inhibitors, a type of diabetes medicine, may affect the kidneys. People can join only if they are already having a kidney biopsy or kidney surgery as part of their regular medical care.\n\nThe main questions this study aims to answer are:\n\n* Do people who take SGLT2 inhibitors show different biological patterns in kidney tissue than similar people who do not take them?\n* Are these kidney tissue patterns linked with how kidney health changes over time?\n\nResearchers will compare participants who take SGLT2 inhibitors with similar participants who do not take these medicines.\n\nParticipants will:\n\nLet researchers use one stored slide of kidney tissue from their regular care (no extra research biopsy) Give a blood sample and a urine sample Let researchers review medical record information over time",[323,324,31,325],"Diabetic Nephropathies","Kidney Diseases","Diabetes Mellitus, Type 2",[327,328,329,330,331,332],"Diabetic nephropathy","Chronic kidney disease","Diabetic kidney disease","Sodium-glucose cotransporter 2 inhibitors","Spatial transcriptomics","Kidney-protective therapy",{"date":334,"type":39},"2026-03-02",{"date":336,"type":39},"2025-11-12",{"date":338,"type":23},"2028-11-12",{"name":229,"class":46},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":320,"phases":4,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":76},"100625364","assessing-hydromorphone-sustained-release-tablets-in-elderly-cancer-pain-patients-with-renal-insufficiency-100625364","NCT07421674","Assessing Hydromorphone Sustained-Release Tablets in Elderly Cancer Pain Patients With Renal Insufficiency","Application Research of Hydromorphinone Sustained-release Tablets in the Treatment of Elderly Patients With Cancer Pain Accompanied by Renal Insufficiency","Inclusion Criteria:\n\n1. Age ≥ 65 years.\n2. Pathologically or cytologically confirmed malignant tumor.\n3. Opioid-naïve patients with moderate-to-severe cancer pain (Numerical Rating Scale score ≥ 4).\n4. Renal function meeting one of the following criteria at baseline:\n\n1）Mild-to-moderate renal insufficiency group: 30 mL\u002Fmin\u002F1.73m² ≤ estimated glomerular filtration rate (eGFR) \\\u003C 90 mL\u002Fmin\u002F1.73m².\n\n2）Normal renal function group: eGFR ≥ 90 mL\u002Fmin\u002F1.73m². 5.Expected survival period ≥ 3 months. 6.Ability to take oral medication and cooperate with study assessments. 7.Willing to participate voluntarily and able to provide signed informed consent.\n\nExclusion Criteria:\n\n1. Severe renal insufficiency (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²) or requirement for renal replacement therapy.\n2. Severe hepatic insufficiency (alanine aminotransferase \u002F aspartate aminotransferase ≥ 2.5 times the upper limit of normal or Child-Pugh Class C).\n3. Paralytic ileus.\n4. Pain of unclear origin or pain that is solely acute\u002Fincident pain.\n5. Symptoms or history of diseases such as intracranial hypertension, head injury, cerebral aneurysm, or other central nervous system disorders.\n6. Symptoms of prostatic hypertrophy, thyroid dysfunction, or urethral stricture. Symptoms of asthma, respiratory obstruction, or respiratory failure.\n7. Known allergy or hypersensitivity to hydromorphone or oxycodone.\n8. Use of monoamine oxidase inhibitors within 14 days prior to enrollment.\n9. Participation in any other clinical trial within 1 month prior to enrollment.\n10. Any other condition considered by the investigator as unsuitable for participation in this study.","65 Years",{"count":349,"type":23},62,"4 Weeks","This clinical study aims to understand whether domestic hydromorphinone sustained-release tablets are effective and safe in treating moderate to severe cancer pain in elderly patients with renal insufficiency.\n\nIt will also understand key safety concerns, especially regarding renal function and neurotoxicity.\n\nThe main questions it aims to answer include:1. Can hydromorphinone sustained-release tablets effectively relieve the pain of such patients and improve their quality of life?2. During the treatment period, what effect does this drug have on renal function (measured by eGFR)? 3. In this specific population, what are the occurrence and characteristics of neurotoxicity and other side effects induced by opioids? Researchers will compare elderly cancer pain patients with renal insufficiency with those with normal renal function (both receiving the study drug treatment) to observe whether there are differences in efficacy and safety results.\n\nParticipants will:\n\nReceive a standardized treatment plan: First, subcutaneous injection of hydromorphinone injection for dose titration, and then switch to daily oral administration of hydromorphinone sustained-release tablets for 4 weeks.\n\nVisit the clinic for assessment and examination (including renal function tests) during the baseline period, on the 7th day, and at the weekends of the 2nd, 3rd, and 4th days.\n\nRegularly monitor and record the degree of pain, the occurrence of explosive pain, the use of medication, and any side effects.",[353,207,354],"Cancer Pain","Hydromorphone Use",[353,271,356,357,358],"Aged","Hydromorphone","Opioid-Induced Neurotoxicity","2026-02-23",{"date":361,"type":39},"2026-02-25",{"date":363,"type":23},"2026-02-10",{"date":365,"type":23},"2028-12-31",{"name":367,"class":46},"Taian Cancer Hospital",{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":375,"targetDuration":376,"studyType":320,"phases":4,"briefSummary":377,"conditions":378,"keywords":382,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":189},"100617004","the-cph-mbd-cohort-dietary-substudy---comparison-of-methods-for-dietary-registrations-100617004","NCT07312981","The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations","The CPH-MBD Cohort - Substudy on Dietary History","Inclusion Criteria:\n\n* A glomerular filtration rate of \\\u003C30 ml ml\u002Fmin\u002F1.73m2\n* 18 years and above\n\nExclusion Criteria:\n\nNone",{"count":22,"type":23},"3 Days","The aim of the study is to assess the association between the calcium and phosphorus balance and the stage of kidney disease measured by creatinine clearence in patients with chronic kidney disease stage 4 and 5. The balance is measured a measurement between the recorded diatery intake and the urinary excretion. Additionally a comparison between image based diatery accessment and weighted records will be measured",[379,207,380,381],"CKD","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder","Pre-dialysis",[383,384,385,386,387,388,389,390,391,392],"Diet","Humans","Observational","Cohort","Phosphate\u002Furine","Calcium\u002Furine","Mineral bone disorder","Elderly","Calcium Balance","Phosphate Balance","2025-12-17",{"date":395,"type":39},"2025-12-31",{"date":397,"type":39},"2025-12-15",{"date":399,"type":23},"2029-05-15",{"name":401,"class":46},"University of Copenhagen",{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":409,"targetDuration":4,"studyType":320,"phases":4,"briefSummary":411,"conditions":412,"keywords":414,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":189},"100464338","renal-biopsies-in-post-liver-transplantation-patients-with-renal-impairment-100464338","NCT05326399","Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment","Renal Biopsies in Post-liver Transplantation Patients With Renal Impairment: a Single-center, Prospective Cohort Study","Inclusion Criteria:\n\n* age 18-75 years\n* patients received liver transplantation\n* new onset of proteinuria(defined as 24-hour proteinuria\\>1g\u002F24h, or Urinary albumin creatinine ratio(UACR)\\>300mg\u002Fg on at least two occasions), and\u002For renal impairment: eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m² at least two occasions, and\u002For serum creatinine increase ≥50% from baseline\n* have received renal biopsy in the past 3 months\n* Signed informed consent form(ICF)\n\nExclusion Criteria:\n\n* patients received renal transplantation\n* hepatic failure\n* severe bleeding risk or platelet \\\u003C70\\*109\u002FL\n* chronic kidney insufficiency with eGFR\\\u003C30ml\u002Fmin·1.73m2,or kidney atrophy, or solitary kidney, or medullary sponge kidney, or polycystic kidney, or obstructive nephropathy\n* uncontrolled mental disease or unable to cooperate during operation\n* Pregnancy or lactation\n* not suitable for this study judged by investigaters",{"count":410,"type":23},369,"Investigators will conduct this single-center, prospective cohort study to explore the prevalence and risk factors of renal function progression in post-liver transplantation patients with renal impairment after renal biospy and to understand the the pathology of kidney disease in post-liver transplantation patients with renal impairment.",[413,31],"Liver Transplantation",[415,416,417],"Liver transplantation","renal biopsy","chronic kidney disease","2025-11-23",{"date":420,"type":39},"2025-11-28",{"date":422,"type":39},"2022-06-01",{"date":424,"type":23},"2030-12-31",{"name":426,"class":46},"RenJi Hospital",{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":433,"eligibilityCriteria":434,"healthyVolunteers":12,"sex":18,"minAge":435,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":24,"phases":438,"briefSummary":439,"conditions":440,"keywords":445,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":76},"100566830","dialysis-with-expanded-solute-removal-100566830","NCT06660277","DIALysis With EXpanded Solute Removal","DIALysis With EXpanded Solute Removal (DIALEX): A Large, Simple Randomized Trial to Evaluate the Major Health Effects of Expanded Versus Conventional Hemodialysis.","DIALEX","Inclusion Criteria: Inclusion requires that all the following are present:\n\n1. One of:\n\n   1. Age 60 years or older; or\n   2. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and\n2. Receiving any form of dialysis regularly for the previous 90 days; and\n3. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and\n4. A valid provincial or territorial health insurance card number.\n\nExclusion Criteria: Patients are ineligible if they meet any of the following criteria:\n\n1. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of:\n\n   1. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or\n   2. Planned to receive HDF; or\n   3. Planned to receive nocturnal HD; or\n   4. Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or\n   5. Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or\n   6. An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or\n   7. Another medical, psychosocial, or logistical reason; or\n2. Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise permits concurrent participation in other trials); or\n3. Previously enrolled in this trial; or\n4. Declined participation.","45 Years",{"count":437,"type":23},4800,[58],"The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:\n\n1\\) Does expanded hemodialysis reduce the risk of death from any cause?\n\nResearchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.\n\nParticipants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux\u002Fexpanded dialysis filter or a high-flux\u002Fconventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).",[441,442,443,444,268,31,269,297],"Chronic Kidney Disease Requiring Hemodialysis","End-Stage Kidney Disease (ESKD)","Chronic Kidney Disease Requiring Chronic Dialysis","Pragmatic Randomized Controlled Trial",[446,447,448,449,450,451,452],"Nipro Elisio HX","RCT","Dialyzer","Hemodialysis Filter","Super-High Flux Dialyzer","High-Flux Dialyzer","Expanded Hemodialysis","2025-08-22",{"date":455,"type":39},"2025-08-28",{"date":457,"type":39},"2025-08-12",{"date":459,"type":23},"2030-08",{"name":461,"class":46},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":347,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":471,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":481,"locationsCount":130},"100577312","early-phase-1-exploring-the-impact-of-nephropathy-formula-no-1-on-chronic-kidney-disease-patients-100577312","NCT06796660","Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","Exploring the Impact of Nephropathy Formula No. 1 on T-Cell Immune Balance in Chronic Kidney Disease Patients Via the IL-6\u002FSTAT3 Signaling Pathway","Inclusion Criteria:\n\n1. Age between 18 and 65 years old (inclusive);\n2. No gender restriction;\n3. Patients diagnosed with CKD stages 2-4 according to the above diagnostic criteria by a specialist physician;\n4. TCM syndrome differentiation is consistent;\n5. Able to cooperate with the study treatment and follow-up, and has good compliance;\n6. Agree and sign the medical informed consent form.\n\nExclusion Criteria:\n\n1. Patients undergoing hemodialysis or peritoneal dialysis;\n2. Patients with severe primary diseases of the cardiovascular, hematological, digestive, nervous, respiratory, endocrine systems, malignant tumors, etc.;\n3. Patients in the active phase of autoimmune system diseases;\n4. Patients with chronic infectious diseases such as active viral hepatitis, HIV, or active tuberculosis;\n5. Patients with recent acute infections, and non-infectious complications such as hypertension and anemia that have not been effectively controlled;\n6. Patients who have taken traditional Chinese medicine related to nephropathy treatment within the past month;\n7. Patients who have undergone surgery, trauma, major bleeding, or blood transfusion within the past three months, or have severe clinical infections, electrolyte disturbances, and acid-base imbalances that have not been effectively controlled;\n8. Pregnant or breastfeeding women;\n9. Patients with mental disorders or poor compliance who cannot cooperate;\n10. Patients who have participated in other drug tests within the past three months or have not completed the effective drug washout period. -",{"count":470,"type":23},70,[472],"EARLY_PHASE1","This study is a prospective randomized controlled trial, enrolling 70 patients with CKD stages 2-4, randomly divided into a control group and a treatment group, with 35 cases in each group. The study subjects are sourced from three centers. The control group receives integrated basic treatment for chronic kidney disease, including dietary nutrition adjustment, blood pressure control, blood sugar control, lipid control, anemia treatment, and regulation of water, electrolyte, and acid-base metabolic balance. The treatment group, in addition to the basic treatment, is administered Nephropathy Formula No. 1 orally, with a treatment course of 12 weeks and a follow-up period of 2 weeks. The outcome measures are the changes in biochemical indicators, inflammatory factors, T cell subsets, STAT3 mRNA expression, and TCM syndrome scores after 12 weeks of treatment, to assess therapeutic efficacy. This study proposes the experimental hypothesis that Nephropathy Formula No. 1 can effectively improve the T cell immune balance in CKD patients by modulating the IL-6\u002FSTAT3 signaling pathway, thereby inhibiting the occurrence and development of renal fibrosis and improving the prognosis of CKD to a certain extent. Specifically, Nephropathy Formula No. 1 may function through the following mechanisms: (1) downregulating IL-6 mRNA expression, reducing IL-6 secretion, and thereby inhibiting the activation of the STAT3 signaling pathway; (2) regulating the balance of Th17\u002FTreg cell subsets, promoting the differentiation of Th17 cells into Treg cells, enhancing the anti-inflammatory and immunosuppressive effects of Treg cells, and alleviating renal inflammatory responses and fibrosis. Through in-depth exploration of this study, it is expected to provide new ideas and methods for the clinical treatment of CKD, with significant scientific and clinical implications.",[31],"2025-08-18",{"date":477,"type":39},"2025-08-19",{"date":479,"type":23},"2025-09-01",{"date":43,"type":23},{"name":482,"class":46},"Liu Zhanghong",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":24,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":507,"locationsCount":130},"100540258","first-in-human-study-to-examine-safety-of-a-new-peritoneal-dialysis-device-weakid-in-end-stage-kidney-disease-patients-100540258","NCT06314503","First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients","Clinical Validation of a Continuous Flow Peritoneal Dialysis System With Dialysate Regeneration","CORDIAL","Inclusion Criteria:\n\n* ≥18 years of age\n* Treated with PD for at least 3 months prior to enrolment\n* Well-functioning peritoneal catheter and no peritoneal catheter replacement for at least a month prior to enrolment\n* No PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished).\n* Previous or current use of Extraneal® with no contra-indications\n* Capable of understanding the patient information sheet and informed consent form (ICF) and give informed consent\n* Willing and able to comply with all study procedures and attend all study visits\n\nExclusion Criteria:\n\n* Patients who are unable to provide informed consent\n* Patients who are unable to comply with study procedures\n* Patients who received renal replacement therapy other than conventional PD less than 8 weeks prior to enrolment\n* Patients who participated in an intervention trial less than 8 weeks prior to enrolment or are currently participating in an intervention trial. Patients in an observational study without any interventions or in post-market surveillance do not need to be excluded.\n* Patients with a PD-related infection (exit-site infection, tunnel infection or peritonitis) less than 8 weeks prior to enrolment (counting from the day that the treatment has been finished)\n* Patients with peritoneal catheter dysfunction or mechanical issues less than one month prior to enrolment\n* Patients who have never used Extraneal® dialysis fluid or have a contra-indication for Extraneal®: a known allergy to cornstarch or icodextrin; maltose or isomaltose intolerance; glycogen storage disease\n* Patients with an incompatible PD connection to the device (e.g. Fresenius PD system)\n* Patients with haemoglobin concentrations \\\u003C 6.2 mmol\u002FL (\\\u003C 10 g\u002FdL) less than 8 weeks prior to enrolment\n* Patients with hyperkalemia (\\> 6.0 mmol\u002FL) or hyponatremia (\\\u003C 130 mmol\u002FL) in the 8 weeks prior to enrolment\n* Patients with hypocalcemia (plasma total calcium concentration corrected for albumin \\\u003C2.20 mmol\u002FL or ionized calcium \\\u003C1.15 mmol\u002FL) or hypomagnesemia (plasma magnesium concentration \\\u003C0.70 mmol\u002FL) in the 8 weeks prior to enrolment\n* Patients with any serious medical condition which in the opinion of the investigator, may adversely affect the safety of the participant and\u002For effectiveness of the study\n* Female patients who are either (planning to become) pregnant within the study period or breast feeding\n* Patients with a life expectancy \\\u003C3 months\n* Anticipated living donor kidney transplantation \\\u003C3 months",{"count":492,"type":23},12,[58],"The goal of this first-in-human clinical trial is to examine the safety and efficacy of treatment with a new peritoneal dialysis (PD) device called WEAKID (WEarable Artificial KIDney for peritoneal dialysis). This device, unlike conventional PD, allows for continuous flow of dialysate inside the abdominal cavity combined with continuous regeneration of spent dialysate thanks to sorbents that remove toxins from the fluid.\n\nThe study will include PD patients of 18 years or older with a well-functioning peritoneal catheter and no history of a PD-related infection for at least eight weeks prior to enrolment.\n\nThe main purpose of this study is to assess the (short-term) safety of the WEAKID system in a limited number (n=12) of patients and sessions.\n\nParticipants will undergo six treatment sessions (of four or eight hours) in total over a period of two weeks, either with or without a sorbent chamber.\n\nParticipants will be asked to collect urine and dialysate the week before the first treatment and during the treatment days. In addition, blood samples will be collected before and during the treatment weeks in order to compare the effects of conventional PD with that of WEAKID treatment. A peritoneal equilibrium test will also be done before and after the treatment weeks to test the function of the lining of the abdomen (the peritoneal membrane).",[31,269,496],"Chronic Kidney Diseases",[498,499,500],"Peritoneal Dialysis","First-in-human","Medical device","2025-07-15",{"date":503,"type":39},"2025-07-18",{"date":505,"type":39},"2024-01-22",{"date":395,"type":23},{"name":508,"class":46},"UMC Utrecht",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":347,"enrollmentInfo":517,"targetDuration":4,"studyType":24,"phases":519,"briefSummary":520,"conditions":521,"keywords":525,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":492},"100568066","phase-4-which-of-the-commonly-available-and-approved-drugs-in-addition-to-standard-of-care-can-significantly-improve-the-slope-of-estimated-glomerular-filtration-rate-at-two-years-when-compared-to-standard-of-care-alone-in-south-asian-kidney-biopsy-proven-adult-18-years-primary-iga-nephropathy-100568066","NCT06676384","Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary IgA Nephropathy: Multi-center, Multi-arm and Multi-stage","IA-GRACE-IgANT","Inclusion Criteria:\n\n1. Must be able to provide a written informed consent form, which must be obtained before the initiation of study assessments.\n2. Adults between 18-65 years of age.\n3. Males or Females.\n4. Diagnosis of primary IgAN as demonstrated by renal biopsy of any vintage if eGFR ≥45 mL\u002Fmin\u002F1.73 m2 or within the last ten years if eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m2. If diabetic, the biopsy vintage should be less than five years.\n5. eGFR ≥20 mL\u002Fmin\u002F1.73 m2 at screening, as per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.\n6. Total urine protein excretion ≥1 g per 24-hour or UPCR ≥ 0.75 g\u002Fg from an adequately measured 24-hour urine sample (24HUP) during the Screening Period.\n7. Patient on the maximum labelled or tolerated dose of ACEi or ARB AND 10mg\u002Fd of Dapagliflozin (SGLT2i) for at least 12 weeks at screening and from screening to study Day 1.\n8. Systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 mmHg at randomisation. Other anti-hypertensives can be optimised during the screening period to achieve the BP goal.\n9. A female is eligible if she is not pregnant and consents to avoid pregnancy during the study duration.\n\nExclusion Criteria:\n\n1. IgAN secondary to another condition (e.g., liver cirrhosis) or other causes of mesangial IgA deposition such as systemic lupus erythematosus (SLE), dermatitis herpetiformis, ankylosing spondylitis, etc. IgA vasculitis (i.e., Henoch-Schonlein purpura) with biopsy-proven mesangial IgA deposition and no active skin vasculitis for the last year can be included.\n2. Evidence of nephrotic syndrome at screening (serum albumin \\\u003C3g\u002FdL AND UPCR \\>3.5 g\u002Fg).\n3. Evidence of rapidly progressive glomerulonephritis defined as loss of ≥ 50% of eGFR in three months before screening.\n4. Concomitant kidney disease in addition to IgAN in kidney biopsy (e.g., diabetic nephropathy, primary focal segmental glomerulosclerosis, membranous nephropathy, C3 glomerulopathy, lupus nephritis).\n5. Female patients planning pregnancy.\n6. Concomitant co-morbidities like systemic autoimmune disorders, chronic active infections like tuberculosis, hepatitis B, hepatitis C and human immunodeficiency virus infection, chronic liver disease, and chronic obstructive pulmonary disease.\n7. Renal or other organ transplantation before, or expected during, the study, except for corneal transplants.\n8. Morbid obesity defined as BMI ≥ 40 kg\u002Fm2 at screening.\n9. Uncontrolled diabetes as defined by HbA1c \\> 8% at screening.\n10. History or diagnosis of demyelinating diseases such as multiple sclerosis or optic neuritis.\n11. Prohibited medications:\n\n    * Participants who received oral steroids over two weeks within 12 weeks before screening.\n    * Immunosuppressive medications (e.g., MMF, azathioprine, cyclophosphamide, hydroxychloroquine) for treating IgAN within 12 weeks before screening.\n    * Use of B-cell-directed biologic therapies, including belimumab, rituximab, and ocrelizumab, within six months before screening.\n    * Use of other biologics (e.g., anti-TNF, abatacept, anti-IL-6) and investigational biologics within the last four weeks or five half-lives, whichever is longer, before the screening.\n    * Use of traditional medications and\u002For Ayurvedic medications within 12 weeks before screening.\n    * Use of endothelin receptor antagonists\u002F oral spironolactone or oral finerenone\u002F GLP-1 agonists\u002F hydroxychloroquine within 12 weeks before screening.\n12. Patients with a history of unstable angina, Class III and IV congestive heart failure, and clinically significant arrhythmia, as judged by the Investigator.\n13. Active clinically significant viral, bacterial, or fungal infection or any major episode of infection requiring hospitalisation or treatment with parenteral anti-infectives within four weeks before or during the Screening Visit.\n14. History of malignancy within the past five years before Screening (except for adequately treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ, with no evidence of recurrence).\n15. Known hypersensitivity to any of the interventions.\n16. Major surgery within six weeks before the Screening Visit.\n17. Clinically significant history of alcohol or drug abuse in the one year before the Screening Visit as per the Investigator's opinion.\n18. Unwillingness or lack of capacity to follow all study procedures.",{"count":518,"type":23},585,[26],"Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019. India is the most populous country in South Asia, with one-fourth of the global population. CKD prevalence has reached epidemic proportions in South Asia, with 1 in 7 adults affected by it. Glomerular diseases are the most common cause of CKD after diabetes and hypertension. IgAN is the most common primary glomerular disease in adults. In the Caucasian and East Asian populations, IgAN results in end-stage kidney disease (ESKD) in 15-20% of patients within 15-20 years after the first clinical presentation.\n\nOur first prospective observational (GRACE-IgANI) cohort since 2015 showed that South Asians have severe and progressive IgAN, with 39% having a rapid fall in eGFR, 25% having non-remission of proteinuria, and 36% reaching an adverse kidney outcome at three years. Our group has shown that South Asian ethnicity is associated with a severe phenotype, rapid progression, and significant ethnic differences in biomarkers.\n\nOver the last few years, newer anti-proteinuric agents and immunomodulatory drugs have either been approved by the FDA or are in the late phases of clinical trials for various proteinuric kidney diseases. The results of the STOP-IgAN and the recent TESTING trial have shown that the short-term beneficial effects of steroids on proteinuria and eGFR slope at six months wane over time, and there is a need for effective longer-term agents. The KDIGO guidelines development body on glomerular diseases has actively advocated enrolling patients prospectively in 'Clinical Trials'.\n\nPlatform trials are Multi-Arm and Multi-Stage (MAMS) randomised CTs comparing multiple parallel interventional groups against standardised common control groups with central coordination. It allows new interventions to be added, the control group to be updated throughout the trial, and the use of prespecified interim analysis plans for statistical efficiencies. Interventional groups can be introduced after the trial has started based on pre-specified criteria, and futile interventions may be stopped based on pre-specified interim analyses and trial-stopping rules.\n\nThis is a randomised controlled single-blind (outcome assessor) Platform trial, Multi-Arm and Multi-Stage. There is a single overarching protocol called a Master protocol. The master protocol, the common concurrent control arm for multiple interventions,the within-trial adaptations, the pre-specified interim analyses, and the pragmatic nature ensure greater acceptability and allow key trial characteristics to evolve. The overall strategy of the study relies strongly on pragmatic 'real world clinical situations' faced by practising nephrologists when treating adult patients with kidney biopsy-proven primary IgAN in South Asia. It will establish the 'GRACE Clinical Trial Network'.\n\nThe overarching trial hypothesis is that commonly available and approved generic drugs (low-dose oral prednisolone, gut-directed budesonide, mycophenolate mofetil, and hydroxychloroquine) in addition to Standard of Care (SoC), which is the maximal labelled or tolerated dose of renin-angiotensin system blockers (ACEi\u002F ARB) and a steady dose of sodium-glucose cotransporter 2 inhibitors (SGLT2i) can significantly improve the kidney outcomes at two years when compared to Standard of Care (SoC) alone in South Asian kidney biopsy-proven adult (≥18 years) primary IgAN who on follow-up remain at high risk of progression defined as UPCR ≥0.75g\u002Fg and baseline eGFR ≥20ml\u002Fmin\u002F1.73m2 despite good BP control. SoC is defined as a maximal labelled or tolerated dose of ACEi\u002F ARB and a steady dose of SGLT2i with a goal BP \\\u003C140\u002F90 mmHg for at least three months.",[522,31,523,524],"IgA Nephropathy","IgA Vasculitis","IGA Glomerulonephritis",[526,527,528,522,328,529,523,530,531],"Platform Trial","Randomised Embedded Trial","MAMS Trial","Glomerulonephritis","Single blind","Treatment","2025-07-10",{"date":534,"type":39},"2025-07-14",{"date":536,"type":39},"2025-02-15",{"date":538,"type":23},"2029-08",{"name":540,"class":46},"Christian Medical College, Vellore, India",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":549,"targetDuration":4,"studyType":24,"phases":551,"briefSummary":552,"conditions":553,"keywords":557,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":76},"100582429","phase-1-probiotic-supplementation-and-disease-progression-in-ckd-a-randomized-trial-100582429","NCT06863194","Probiotic Supplementation and Disease Progression in CKD: A Randomized Trial","Effects of Probiotic Supplementation on Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease: A Randomized Controlled Trial","PRO-CKD","Inclusion Criteria:\n\n* Adults aged ≥ 18 years (both males and females).\n* Diagnosed with Chronic Kidney Disease (CKD) Stage III or IV, confirmed by eGFR.\n* Stable medical condition with no recent hospitalization for acute kidney injury or other serious illnesses.\n* Not currently on probiotic supplementation or prebiotic therapy.\n* Willing to provide informed consent and comply with the study protocol, including clinic visits and sample collection.\n\nExclusion Criteria:\n\n* CKD Stage I, II, or V, or on dialysis.\n* Currently using probiotics or prebiotics as part of their diet or treatment.\n* History of active malignancy (cancer) or undergoing chemotherapy.\n* Significant gastrointestinal disease (e.g., inflammatory bowel disease, irritable bowel syndrome, or recent GI surgery).\n* Pregnant or breastfeeding women (due to safety concerns).\n* Patients with autoimmune diseases (e.g., lupus, rheumatoid arthritis).\n* Individuals on long-term antibiotic or anti-inflammatory medication that could interfere with microbiota composition.\n* Individuals with severe behavioral or cognitive disorders that may prevent adherence to the study protocol.",{"count":550,"type":23},72,[242,113],"The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients.\n\nThe main questions the study aims to answer are:\n\nDoes probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients?\n\nParticipants will:\n\nBe randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.",[554,31,555,556],"Kidney Disease, Chronic","Gut Dysbiosis","Uremic Toxins",[558,559,560,556,561,562,563,564],"Chronic Kidney Disease (CKD)","Probiotics","Gut Microbiota","Indoxyl Sulfate (IS)","Inflammation in CKD","Dysbiosis in CKD","Lactobacillus plantarum","2025-05-13",{"date":567,"type":39},"2025-05-16",{"date":569,"type":39},"2025-04-03",{"date":571,"type":23},"2025-10-20",{"name":573,"class":46},"Mansoura University",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":582,"targetDuration":4,"studyType":320,"phases":4,"briefSummary":584,"conditions":585,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":595},"100281065","feasibility-of-estimating-the-prevalence-and-management-of-stage-4-ckd-the-gard-france-100281065","NCT02938611","Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France","Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France","MRC-Gard","Inclusion Criteria:\n\n* chronic kidney disease (stage \\>= 4)\n\nExclusion Criteria:\n\n\\-",{"count":583,"type":23},3375,"The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.",[31],"2025-03-07",{"date":588,"type":39},"2025-03-10",{"date":590,"type":39},"2019-01-01",{"date":592,"type":23},"2025-12",{"name":594,"class":46},"Centre Hospitalier Universitaire de Nīmes",4,{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":604,"targetDuration":4,"studyType":24,"phases":606,"briefSummary":607,"conditions":608,"keywords":612,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":622,"locationsCount":76},"100582758","effects-of-exogenous-ketosis-on-proteinuria-and-renal-function-100582758","NCT06867471","Effects of Exogenous Ketosis on Proteinuria and Renal Function","Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Patients with Polycystic Kidney Disease","KETO-CKD","Inclusion Criteria\n\nStudy A (patients with CKD):\n\n* ACR \\> 200 mg\u002Fg \\\u003C3000 mg\u002Fg\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nStudy B (patients with PKD):\n\n* Prior diagnose with PKD\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nExclusion Criteria (Study A+B)\n\n* Diabetes Mellitus type 1\n* Heart Failure\n* Liver Disease\n* Kidney transplant\n* Malignant diseases (except skin cancer)\n* Recent acute myocardial infarction (AMI), apoplexia\u002Ftransient ischemic attack (TIA) (within 3 months of inclusion)\n* Pregnancy or breast feeding\n* Alcohol or drug abuse\n* Periodic fasting within four weeks of inclusion\n* Routinely intake of ketogenic diet within four weeks of inclusion\n* Treatment with nitrate",{"count":605,"type":23},43,[58],"A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.",[31,609,610,611],"Polycystic Kidney Diseases","Proteinuria","Ketosis",[613,614,615,611,610,616],"Kidney physiology","Glomerular Filtration Rate","Chronic Kidney disease","Natriuresis","2025-03-06",{"date":588,"type":39},{"date":620,"type":39},"2024-09-11",{"date":592,"type":23},{"name":623,"class":46},"Gødstrup Hospital",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":24,"phases":634,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":76},"100579544","guideline-directed-management-for-chronic-kidney-disease-evaluation-of-an-education-progamme-in-a-national-cluster-randomized-controlled-trial-100579544","NCT06825676","Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial","Guideline-diRected MAnagement for Chronic Kidney Disease: EValuation of an Education Progamme in a National Cluster Randomized Controlled Trial (GRAVER)","GRAVER","Inclusion Criteria:\n\nPatients with chronic kidney disease (CKD) (defined as eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² or UACR \\>30 mg\u002Fg on two occasions at least 3 months apart).\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Patients with end-stage renal disease (eGFR \\\u003C15 ml\u002Fmin\u002F1.73 m²) or those already receiving regular dialysis or kidney transplantation\n3. Pregnant or breastfeeding women\n4. Patients currently participating in any other clinical trial\n5. Patients who exhibit characteristics during the screening phase that indicate an inability to complete the study",{"count":633,"type":23},1800,[58],"Study Objective:\n\nTo evaluate the impact of guideline-based CKD comprehensive management medical re-education for community healthcare providers on improving cardio-renal outcomes in CKD patients.\n\nStudy Design:\n\nA nationwide, multicenter, prospective, cluster-randomized controlled trial.\n\nInclusion and Exclusion Criteria:\n\nInclusion Criteria: Chronic kidney disease (CKD) patients meeting the following criteria:\n\neGFR \\\u003C60 mL\u002Fmin\u002F1.73 m² or UACR \\>30 mg\u002Fg on two separate occasions at least 3 months apart.\n\nExclusion Criteria:\n\nAge \\\u003C18 years. End-stage renal disease (ESRD) with eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m², or patients already on regular dialysis or having received a kidney transplant.\n\nPregnant or breastfeeding women. Patients participating in any other clinical trials. Patients who exhibit characteristics at the screening stage that suggest they are unable to complete the study.\n\nIntervention:\n\nControl Group: Routine community training and management. Intervention Group: Training for community healthcare providers on guideline-based CKD management, including lifestyle management, risk assessment and referral recommendations, risk factor control, pharmacological treatment, and the application of a CKD management checklist incorporating these components.\n\nEfficacy Evaluation Indicators:\n\nPrimary Outcome:\n\nA renal composite endpoint, defined as at least a 25% decline in eGFR, progression to ESRD (dialysis, kidney transplantation, or sustained eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²), or death due to renal or cardiovascular causes.\n\nSecondary Outcomes:\n\nCardiovascular composite endpoint: cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, and hospitalization for heart failure.\n\nDelayed CKD progression, defined as a reduction in the annual eGFR decline rate by 0.5-1 mL\u002Fmin\u002F1.73 m² or a 30% reduction in UACR per year.\n\nProportion of patients receiving guideline-recommended pharmacological treatment.\n\nSafety Evaluation Indicators:\n\nAcute deterioration of renal function (serum creatinine increase \\>30% within 4 weeks).\n\nNew-onset hyperkalemia. Symptomatic hypotension. Recurrent hypoglycemia.",[31,637],"Cardiovascular Diseases (CVD)","2025-02-09",{"date":640,"type":39},"2025-02-13",{"date":642,"type":23},"2025-03",{"date":644,"type":23},"2027-03",{"name":646,"class":46},"Guangdong Provincial People's Hospital",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":654,"targetDuration":4,"studyType":24,"phases":656,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":76},"100565953","phase-1-pk-and-pd-of-yg1699-in-ckd-patients-with-diabetes-100565953","NCT06648876","PK and PD of YG1699 in CKD Patients With Diabetes","Pharmacokinetic and Pharmacodynamics of YG1699 in Patients With Diabetes and Kidney Dysfunction","Inclusion Criteria:\n\n1. Ability to provide informed consent\n2. Male or female patients ,age between 18 and 70 at screening\n3. Meet the diagnostic criteria for diabetic nephropathy, including patients with type 1 or type 2 diabetes;\n4. Fasting blood glucose \\\u003C11.1 mmol\u002FL, stable on baseline anti-diabetic medication\n5. No history of SGLT2i use within the past month\n6. Hemodialysis patients must have maintenance hemodialysis for more than 3 months, with 3 sessions per week (limited to HD or HDF treatment), and spKt\u002FV\\>1.2 within 6 months\n7. The patient has not used glucocorticoids, calcineurin inhibitors (cyclosporine, tacrolimus), etc. that affect blood sugar within the past month before signing the informed consent form\n8. The baseline diabetes management medication regimen has been stable within the past 2 weeks.\n\nExclusion Criteria:\n\n1. Hypoglycemia occurs more than 2 times in one month\n2. History of ketoacidosis\n3. Patients who are being treated with swiram and digoxin\n4. Patients with acute kidney injury (serum creatinine increased by ≥ 50% within 1 week)\n5. Abnormal liver function (ALT \\> 3 times the upper limit of normal value)\n6. Hemoglobin \\\u003C 80g\u002FL or \\> 150g\u002FL\n7. The blood pressure of patients with recent symptomatic hypotension is lower than 90\u002F60 mmHg\n8. There is acute myocardial infarction stroke infection in the past month\n9. There is systemic active infection or uncured tumor\n10. The dialysis regimen of HD patients included HP treatment\n11. Participating in other interventional clinical studies\n12. Pregnant or lactating women\n13. Other situations that the researcher thinks are not suitable for joining the study",{"count":655,"type":23},20,[242],"The goal of this clinical trial is to learn PK and PD of YG1699 in patients with diabetes and renal dysfuction.\n\nParticipants will:\n\nTake YG1699 or a placebo every day for 8 days. Visit the clinic 7 times for checkups and tests. Keep a diary of their symptoms. Estimate PK data from a single dose of YG1699. Estimate PD data at baseline and the last day.",[659,31,297],"Diabetes",[661,662,663,379,659],"PK","PD","SGLT1\u002F2 inhibitor","2024-10-17",{"date":666,"type":39},"2024-10-18",{"date":668,"type":23},"2024-10-31",{"date":670,"type":23},"2025-10-30",{"name":426,"class":46},{"id":673,"slug":674,"hasResults":12,"nctId":675,"briefTitle":676,"officialTitle":677,"acronym":4,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":679,"enrollmentInfo":680,"targetDuration":4,"studyType":24,"phases":682,"briefSummary":683,"conditions":684,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":685,"lastUpdatePostDateStruct":686,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":4},"100554702","effects-of-whole-body-electrostimulation-on-patients-with-chronic-kidney-disease-100554702","NCT06502522","Effects of Whole-body Electrostimulation on Patients With Chronic Kidney Disease","Effects of Whole-body Electrostimulation on Kidney Function and Physical Capacity of Patients With Chronic Kidney Disease: Randomized Clinical Trial","Inclusion Criteria:\n\n* Patients diagnosed with CKD (≥ 3 months) in stages 3-4 (GFR between 59 and 15 ml\u002Fmin\u002F1.73m2);\n* Age between 18 and 80 years old;\n* Functional capacity ≥ 300 meters in the six-minute walk test.\n\nExclusion Criteria:\n\n* Cognitive dysfunction that prevents assessments from being carried out or inability to understand and sign the informed consent form;\n* Intolerance to electrical stimulator and\u002For changes in skin sensitivity;\n* Skin injuries or burns where the electrodes are positioned;\n* Patients with stroke sequelae;\n* Recent acute myocardial infarction (two months);\n* Uncontrolled hypertension (SBP\\>230 mmHg and DBP\\>120 mmHg);\n* New York Heart Association grade IV heart failure or decompensated;\n* Unstable angina or arrhythmia;\n* Artificial cardiac pacemaker or implantable cardioverter defibrillator;\n* Peripheral vascular changes in the lower limbs such as deep vein thrombosis;\n* Disabling osteoarticular or musculoskeletal disease;\n* Uncontrolled diabetes (glycemia \\> 300mg\u002FdL);\n* Patients with cancer and\u002For undergoing oncological treatment;\n* Epilepsy;\n* Hemophilia;\n* Chronic obstructive pulmonary disease;\n* Grade II obesity (BMI≥35).","80 Years",{"count":681,"type":23},30,[58],"Chronic kidney disease (CKD) consists of kidney damage, with consequent progressive and irreversible loss of kidney function. In the early stages of the disease, a reduction in circulating levels of the α-klotho protein is already observed, which is related to worsening renal function. Therapeutic strategies that increase serum levels of α-klotho may be of great value in the treatment of CKD. Electrical stimulation contributes to the reduction of reactive oxygen species, DNA damage and improves the effectiveness rate of dialysis, suggesting a systemic effect in patients with terminal CKD. The objective of this study is to evaluate the effects of whole body electrical stimulation on renal function and physical capacity in patients with CKD not dependent on dialysis.",[31],"2024-07-16",{"date":687,"type":39},"2024-07-18",{"date":689,"type":23},"2024-08-01",{"date":691,"type":23},"2025-03-01",{"name":693,"class":46},"Federal University of Health Science of Porto Alegre",{"id":695,"slug":696,"hasResults":12,"nctId":697,"briefTitle":698,"officialTitle":699,"acronym":4,"eligibilityCriteria":700,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":347,"enrollmentInfo":701,"targetDuration":4,"studyType":24,"phases":703,"briefSummary":704,"conditions":705,"keywords":706,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":713,"completionDateStruct":715,"leadSponsor":717,"locationsCount":719},"100382768","phase-4-huaiqihuang-granule-in-the-treatment-of-primary-glomerulonephritis-of-stage-ckd3-100382768","NCT04263922","Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3","Huaiqihuang Granules in the Treatment of Primary Glomerulonephritis of Stage CKD3: a Randomized, Double-blind, Double-simulation, Positive Parallel Control Multi-center Clinical Study","Inclusion Criteria:\n\n1. Diagnosed as primary glomerulonephritis by renal biopsy\n2. Male or female, 18≤age≤65\n3. Blood pressure can be effectively controlled at or below 140\u002F90mmHg\n4. 30mL\u002F（min.1.73m2）≤ eGFR\\\u003C60mL\u002F（min.1.73m2）\n5. 24-hour urine protein ration ≤ 2.0g\u002F24h\n6. The participants must be capable of understanding and comply with the protocol and sign a written informed consent document\n\nExclusion Criteria:\n\n1. Diagnosed as secondary glomerulonephritis\n2. Exposure to corticosteroids, immunosuppressors, tripterygium glycosides, ARBs or ACEIs, without a two weeks washout period\n3. Blood pressure \\\u003C 90\u002F60 mmHg\n4. Serum potassium \\> 5.5 mmol\u002FL\n5. Serum albumin \\\u003C 30g\u002FL\n6. Unilateral or bilateral renal artery stenosis\n7. Pregnant or lactating women, and participants (including males) who were unable or unwilling to take adequate contraception during the study period\n8. Having comorbidities that affect the progression of primary glomerulonephritis (including but not limited to Malignant tumors, Systemic autoimmune diseases, Liver cirrhosis, Diabetes, and Gout)\n9. Allergic to the Huaiqihuang Granule or valsartan\n10. Participating in another clinical trial\n11. Investigators do not think it suitable for a participant to join this study",{"count":702,"type":23},466,[26],"This is a multicentre prospective, randomized, double-blind and imitation, positive-drug parallel controlled clinical trail. The objective of this study is to evaluate the efficacy and safety of Huaiqihuang Granule in patients with CKD stage 3 primary glomerulonephritis.",[31],[707,708,709],"Primary Glomerulonephritis","Huaiqihuang Granule","CKD3","2024-07-10",{"date":712,"type":39},"2024-07-12",{"date":714,"type":39},"2020-06-30",{"date":716,"type":23},"2026-03-30",{"name":718,"class":46},"The First Affiliated Hospital of Dalian Medical University",34]